Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Multicenter retrospective analysis of patients with plasma cell leukemia treated with BCMA-directed CAR-T (ide-cel or cilta-cel) finds overall median PFS was 9.0 months (95% CI 4-15) and median overall survival was 13.0 months.”
Title: Safety and Efficacy of BCMA-directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia
Authors: Gliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna Hovanky, Leyla Shune, Joseph P. McGuirk, Gabriel de Avila, Jack Khouri, Danai Dima, Mahmoud R. Gaballa, Binod Dhakal, Peter A Forsberg, Amandeep Godara, Aimaz Afrough, Larry D. Anderson, Jr., Megan M. Herr, James A Davis, Hashim Mann, Sneha Purvey, William Bennett Clark, Myo Myo Htut, Amer M. Beitinjaneh, Denise L. Pereira, Mehmet Kocoglu, Christopher J Ferreri, Shebli Atrash, Peter M Voorhees, Adriana C Rossi, Shambavi Richard, Hamza Hashmi, Krina K. Patel, Surbhi Sidana, Yi Lin, Doris K Hansen, Douglas W SborovCorresponding
You can read the Full Article on Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
